Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) have received an average rating of "Moderate Buy" from the five brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $4.1875.
LUCD has been the topic of a number of recent analyst reports. Maxim Group cut their price objective on shares of Lucid Diagnostics from $3.00 to $2.00 and set a "buy" rating on the stock in a research note on Friday, May 15th. Ascendiant Capital Markets increased their target price on shares of Lucid Diagnostics from $9.00 to $9.25 and gave the company a "buy" rating in a research report on Monday, June 8th. BTIG Research reissued a "buy" rating and set a $2.50 target price on shares of Lucid Diagnostics in a research note on Monday. Wall Street Zen cut shares of Lucid Diagnostics from a "hold" rating to a "sell" rating in a research note on Saturday, July 4th. Finally, Weiss Ratings downgraded shares of Lucid Diagnostics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday.
Get Our Latest Report on LUCD
Lucid Diagnostics Price Performance
LUCD opened at $0.96 on Friday. Lucid Diagnostics has a 12 month low of $0.86 and a 12 month high of $1.63. The stock has a market cap of $195.19 million, a P/E ratio of -2.04 and a beta of 1.08. The stock's 50 day moving average price is $0.99 and its 200 day moving average price is $1.12.
Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). The business had revenue of $1.47 million for the quarter, compared to the consensus estimate of $1.43 million. Equities analysts anticipate that Lucid Diagnostics will post -0.23 EPS for the current year.
Institutional Investors Weigh In On Lucid Diagnostics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in LUCD. Centiva Capital LP acquired a new stake in Lucid Diagnostics in the third quarter worth approximately $25,000. Cubist Systematic Strategies LLC bought a new stake in shares of Lucid Diagnostics in the 1st quarter worth $39,000. Abel Hall LLC bought a new stake in shares of Lucid Diagnostics in the 4th quarter worth $33,000. JPMorgan Chase & Co. lifted its holdings in shares of Lucid Diagnostics by 71,026.1% in the second quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company's stock valued at $38,000 after buying an additional 32,672 shares during the period. Finally, Pine Valley Investments Ltd Liability Co lifted its holdings in shares of Lucid Diagnostics by 73.2% in the first quarter. Pine Valley Investments Ltd Liability Co now owns 34,283 shares of the company's stock valued at $39,000 after buying an additional 14,487 shares during the period. Institutional investors own 74.01% of the company's stock.
About Lucid Diagnostics
(
Get Free Report)
Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company's flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid's CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.
Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Lucid Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lucid Diagnostics wasn't on the list.
While Lucid Diagnostics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
